Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ NATO selects Saab′s GlobalEye (Cision) +++ SAAB Aktie +5,66%

VICORE PHARMA Aktie

 >VICORE PHARMA Aktienkurs 
1.42 EUR    +15.8%    (TradegateBSX)
Ask: 1.436 EUR / 1800 Stück
Bid: 1.418 EUR / 1800 Stück
Tagesumsatz: 7411 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>VICORE PHARMA Performance
1 Woche: +10,7%
1 Monat: +22,9%
3 Monate: +29,8%
6 Monate: +24,1%
1 Jahr: +81,8%
laufendes Jahr: +15,8%
>VICORE PHARMA Aktie
Name:  VICORE PHARMA HOLDING AB
Land:  Schweden
Sektor:  Gesundheit
ISIN/ Wkn:  SE0007577895 / A14W4W
Symbol/ Ticker:  6Y4 (Frankfurt)
Kürzel:  FRA:6Y4, ETR:6Y4, 6Y4:GR
Index:  -
Profil:  Vicore Pharma Holding AB is a clinical-stage pharmaceutical company based in Sweden, specializing in the development of innovative therapies targeting severe respiratory and fibrotic diseases, particularly through angiotensin II type 2 receptor agoni..
>Volltext..
Marktkapitalisierung:  340.4 Mio. EUR
Unternehmenswert:  243.94 Mio. EUR
Umsatz:  0.32 Mio. EUR
EBITDA:  -44.7 Mio. EUR
Nettogewinn:  -43.65 Mio. EUR
Gewinn je Aktie:  -0.17 EUR
Schulden:  -
Liquide Mittel:  34.71 Mio. EUR
Operativer Cashflow:  -37.46 Mio. EUR
Bargeldquote:  12.52
Umsatzwachstum:  -41.58%
Gewinnwachstum:  -51.09%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel -
Suchwörter:  VICORE PHARMA
Letzte Datenerhebung:  07.07.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 281.53 Mio. St.
Frei handelbar: 64.67%
Leerverk. Aktien: -
Rückkaufquote: -11.63%
Mitarbeiter: 37
Umsatz/Mitarb.: 0.01 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 258.32%
Bewertung:
KGV: -
KGV lG: -
KUV: 870.89
KBV: 3.43
PEG-Ratio: -19.08
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -13454.92%
Operative Marge: -13779.08%
Managementeffizenz:
Gesamtkaprendite: -43.93%
Eigenkaprendite: -47.19%
>Peer Group
Gesundheit, Lungenerkrankungen & -behandlung/ Asthma, Medizinprodukte & -technik/ Implantate/ Wundpflege, Psychische Erkrankungen/ Depressionen/ Schizophrenie
 
07.07.26 - 08:31
Vicore Pharma Holding: Vicore Pharma to Participate in the Leerink Therapeutics Forum (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / July 7, 2026 / Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class o......
06.07.26 - 08:30
Vicore Pharma Holding: Vicore Pharma Appoints Rob Slack as Chief Scientific Officer (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / July 6, 2026 / Vicore Pharma Holding (STO:VICO) - Dr. Slack brings over 20 years' experience in fibrosis and respiratory translational science and joins from GSK, ......
01.07.26 - 23:06
Vicore Pharma Holding: Vicore Pharma to Commence Trading in the United States on the Nasdaq Stock Market (Accesswire)
 
STOCKHOLM, SE AND CAMBRIDGE, MA / ACCESS Newswire / July 1, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(Nasdaq US:VCRE), a clinical-stage biopharmaceutical company unlocking the potenti......
02.06.26 - 08:42
Vicore Pharma Holding: Vicore Pharma to Host Webcast to Discuss Buloxibutid and the Evolving IPF Treatment Landscape (Accesswire)
 
STOCKHOLM, SE AND CAMBRIDGE, MA / ACCESS Newswire / June 2, 2026 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 (AT2) receptor agoni......
26.05.26 - 08:30
Vicore Pharma Holding: Vicore Pharma to Present at the Jefferies Global Healthcare Conference (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / May 26, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 (AT2) receptor agonists, ......
22.05.26 - 15:18
Vicore Pharma Holding: Vicore Pharma Pursues US Dual Listing, Files Registration Statement with the SEC (Accesswire)
 
Proposed dual listing expected to broaden access to US investors as buloxibutid advances toward its Phase 2b readout in IPF, with no concurrent financing or share offering planned STOCKHOLM, SWEDEN......
07.05.26 - 08:30
Vicore Pharma Holding: Vicore Pharma Elects Peter Guenter to its Board of Directors (Accesswire)
 
Appointment strengthens Vicore's board with nearly four decades of global pharmaceutical leadership as the company advances buloxibutid toward an important late-stage data readout STOCKHOLM, SE / A......
06.05.26 - 16:54
Announcement from the Annual General Meeting of Vicore Pharma Holding AB (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / May 6, 2026 / Today on 6 May 2026, the Annual General Meeting (the "AGM") of Vicore Pharma Holding AB (publ) ("Vicore Pharma" or the "Company")(STO:VICO) was held,......
06.05.26 - 08:30
Vicore Pharma Holding: Interim Report January - March 2026 (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / May 6, 2026 / Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), ......
29.04.26 - 08:30
Vicore Pharma Holding: Vicore Pharma Announces Presentations at the 2026 American Thoracic Society International Conference (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / April 29, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, an......
22.04.26 - 08:27
Vicore Pharma Holding: Vicore Pharma Completes Enrollment in the Phase 2b ASPIRE Trial of Buloxibutid in Idiopathic Pulmonary Fibrosis (Accesswire)
 
The randomized Phase 2b ASPIRE trial successfully completed planned enrollment of over 360 patients, reflecting strong execution and robust site engagementASPIRE is designed to assess the effect of......
01.04.26 - 09:30
Notice Of Annual General Meeting In Vicore Pharma Holding AB (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / April 1, 2026 / The shareholders of Vicore Pharma Holding AB (publ)(STO:VICO), reg. no. 556680-3804 (the "Company"), are summoned to the Annual General Meeting on ......
26.03.26 - 08:30
Vicore Pharma Holding: Vicore Publishes the Annual Report for 2025 (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / March 26, 2026 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today an......
09.03.26 - 08:30
Vicore Pharma Holding: Vicore Pharma to Present at Upcoming Investor Conferences (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / March 9, 2026 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today ann......
05.03.26 - 08:30
Vicore Pharma Holding: Vicore Pharma Elevates Leadership Team Ahead of Key Clinical and Corporate Milestones (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / March 5, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAG......
27.02.26 - 08:30
Vicore Pharma Holding: Year-End Report 2025 (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / February 27, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (A......
26.02.26 - 08:30
Vicore Pharma Holding: Vicore Pharma to Present at Upcoming Investor Conferences (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / February 26, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor a......
18.02.26 - 08:30
Vicore Pharma Holding: Vicore Pharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / February 18, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor a......
07.01.26 - 08:30
Vicore Pharma Holding: Vicore Pharma to Present at the 44th Annual J.P. Morgan Healthcare Conference (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / January 7, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor ago......
19.12.25 - 08:36
Vicore Pharma Holding: Vicore Pharma To Move To The Nasdaq Stockholm Mid Cap Segment (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / December 19, 2025 / Vicore Pharma Holding AB (publ) (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs)......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Ubi lex, ibi poena - Wo ein Gesetz, da auch eine Strafandrohung. - Nomen Nescio
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!